| Year |
Citation |
Score |
| 2024 |
Hirode G, Hansen BE, Chen CH, Su TH, Wong GLH, Seto WK, Furquim d'Almeida A, Papatheodoridi M, Brakenhoff SM, Lens S, Choi HSJ, Chien RN, Feld JJ, Forns X, Sonneveld MJ, et al. Limited sustained remission after nucleos(t)ide analogue withdrawal: Results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study). The American Journal of Gastroenterology. PMID 38483300 DOI: 10.14309/ajg.0000000000002759 |
0.329 |
|
| 2024 |
Hirode G, Hansen BE, Chen CH, Su TH, Wong G, Seto WK, Van Hees S, Papatheodoridi M, Brakenhoff SM, Lens S, Choi HSJ, Chien RN, Feld JJ, Forns X, Sonneveld MJ, et al. Erratum: Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study). The American Journal of Gastroenterology. PMID 38457250 DOI: 10.14309/ajg.0000000000002718 |
0.3 |
|
| 2024 |
Choi WM, Yip TC, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Clark LJ, Jafry Z, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, et al. Chronic Hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients. Hepatology (Baltimore, Md.). PMID 38436992 DOI: 10.1097/HEP.0000000000000752 |
0.363 |
|
| 2023 |
Hsiao YW, Sou FM, Wang JH, Chen YH, Tsai MC, Hu TH, Hung CH, Chen CH, Kuo YH. Well-controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib. The Kaohsiung Journal of Medical Sciences. PMID 37843189 DOI: 10.1002/kjm2.12757 |
0.373 |
|
| 2023 |
Chen CH, Peng CY, Hu TH, Wang JH, Hung CH, Lu SN. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics. PMID 37265196 DOI: 10.1111/apt.17602 |
0.31 |
|
| 2023 |
Wang HW, Chen CY, Lai HC, Hu TH, Su WP, Lu SN, Hung CH, Chuang PH, Wang JH, Chen CH, Peng CY. Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy. American Journal of Cancer Research. 13: 526-537. PMID 36895986 |
0.35 |
|
| 2023 |
Hur MH, Park MK, Cheuk-Fung Yip T, Chen CH, Lee HC, Choi WM, Kim SU, Lim YS, Park SY, Lai-Hung Wong G, Sinn DH, Jin YJ, Kim SE, Peng CY, Shin HP, ... Chen CY, et al. Personalized Antiviral Drug Selection in Chronic Hepatitis B Patients Using a Machine Learning Model: A Multinational Study. The American Journal of Gastroenterology. PMID 36881437 DOI: 10.14309/ajg.0000000000002234 |
0.312 |
|
| 2023 |
Hirode ASG, Hansen BE, Chen CH, Su TH, Wong G, Seto WK, Van Hees S, Papatheodoridi M, Brakenhoff SM, Lens S, Choi HS, Chien RN, Feld JJ, Forns X, Sonneveld MJ, et al. Incidence of hepatic decompensation after nucleos(t)ide analogue withdrawal: Results from a large, international, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study). The American Journal of Gastroenterology. PMID 36719174 DOI: 10.14309/ajg.0000000000002203 |
0.339 |
|
| 2022 |
Kee KM, Chen CH, Hu JT, Huang YH, Wang TE, Chau GY, Chen KH, Chen YL, Lin CC, Hung CF, Huang SF, Liu TW, Ku HY, Huang BS, Wang YP, et al. Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019. Viruses. 15. PMID 36680166 DOI: 10.3390/v15010126 |
0.313 |
|
| 2022 |
Choi WM, Cheuk-Fung Yip T, Lai-Hung Wong G, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: individual patient data meta-analysis. Journal of Hepatology. PMID 36572349 DOI: 10.1016/j.jhep.2022.12.007 |
0.351 |
|
| 2022 |
Chang KC, Lin MT, Wang JH, Hung CH, Chen CH, Chiu SY, Hu TH. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral. Viruses. 14. PMID 36560675 DOI: 10.3390/v14122671 |
0.368 |
|
| 2022 |
Chen CH, Hu TH, Wang JH, Lai HC, Hung CH, Lu SN, Peng CY. A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy. Cancers. 14. PMID 36291847 DOI: 10.3390/cancers14205063 |
0.302 |
|
| 2022 |
Kuo YH, Huang TH, Wang JH, Chen YY, Tsai MC, Chen YH, Lu SN, Hu TH, Chen CH, Hung CH. Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib. Cancers. 14. PMID 36010961 DOI: 10.3390/cancers14163971 |
0.369 |
|
| 2022 |
Choi HSJ, Hirode G, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong GLH, Brakenhoff SM, Chien RN, Feld JJ, Sonneveld MJ, Chan HLY, Forns X, et al. Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 35863683 DOI: 10.1016/j.cgh.2022.07.005 |
0.31 |
|
| 2021 |
Tsai MC, Wang CC, Lee WC, Lin CC, Chang KC, Chen CH, Hung CH, Lin MT, Hsiao CC, Chen CL, Chien RN, Hu TH. Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection. Liver Cancer. 11: 22-37. PMID 35222505 DOI: 10.1159/000518940 |
0.334 |
|
| 2021 |
Kuo YH, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus. The Kaohsiung Journal of Medical Sciences. PMID 34687140 DOI: 10.1002/kjm2.12465 |
0.314 |
|
| 2021 |
Pei SN, Liu YF, Kuo CY, Wang MC, Ma MC, Liao CK, Ng HY, Chen CH. Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab. Leukemia & Lymphoma. 1-8. PMID 34323157 DOI: 10.1080/10428194.2021.1948034 |
0.323 |
|
| 2021 |
Wang MH, Kuo YH, Yen YH, Lu SN, Wang JH, Chen CH, Hung CH, Kee KM. Hepatic Abscess Formation after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: Report of a Rare Case. Case Reports in Oncology. 14: 906-911. PMID 34267637 DOI: 10.1159/000517024 |
0.33 |
|
| 2021 |
Lee YC, Wang JH, Chen CH, Hung CH, Lo KC, Yen YH, Kee KM, Hu TH, Lu SN, Kuo YH. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study. The Kaohsiung Journal of Medical Sciences. PMID 34166565 DOI: 10.1002/kjm2.12413 |
0.371 |
|
| 2021 |
Peng CY, Chen CH. On-treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 33966332 DOI: 10.1111/liv.14934 |
0.338 |
|
| 2021 |
Kuo YH, Wang JH, Hung CH, Lu SN, Hu TH, Chen CH. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatology International. PMID 33665773 DOI: 10.1007/s12072-021-10159-w |
0.316 |
|
| 2020 |
Chen CH, Chen CY, Wang JH, Lai HC, Hung CH, Lu SN, Peng CY. Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study. American Journal of Cancer Research. 10: 3882-3895. PMID 33294274 |
0.356 |
|
| 2020 |
Hu TH, Yueh-Hsia Chiu S, Tseng PL, Chen CH, Lu SN, Wang JH, Hung CH, Kee KM, Lin MT, Chang KC, Lin MC, Chien RN. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan. Alimentary Pharmacology & Therapeutics. PMID 33111400 DOI: 10.1111/apt.16116 |
0.372 |
|
| 2020 |
Lin MT, Chang KC, Yen YH, Tsai MC, Chen CH, Wang JH, Hsiao CC, Chiu YH, Hu TH. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. Journal of the Formosan Medical Association = Taiwan Yi Zhi. PMID 32718890 DOI: 10.1016/j.jfma.2020.07.019 |
0.397 |
|
| 2020 |
Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, Peng CY, Chen CH. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatology International. PMID 32319045 DOI: 10.1007/s12072-020-10031-3 |
0.326 |
|
| 2020 |
Hsieh YC, Lin CL, Hung CH, Chen CH, Tung SY, Lin CY, Hu TH, Lu SN, Chien RN, Sheen IS. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects. Journal of Viral Hepatitis. PMID 32039536 DOI: 10.1111/jvh.13262 |
0.316 |
|
| 2019 |
Kuo YH, Wang JH, Chang KC, Hung CH, Lu SN, Hu TH, Yen YH, Kee KM, Chen CH. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. Investigational New Drugs. PMID 31701431 DOI: 10.1007/s10637-019-00870-9 |
0.337 |
|
| 2019 |
Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, et al. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. The American Journal of Gastroenterology. PMID 31634265 DOI: 10.14309/Ajg.0000000000000428 |
0.365 |
|
| 2019 |
Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, et al. REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy. The Journal of Infectious Diseases. PMID 31550363 DOI: 10.1093/Infdis/Jiz477 |
0.327 |
|
| 2019 |
Wang JH, Hu TH, Chen CH, Hung CH, Yen YH, Chang KC, Lu SN. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. The Kaohsiung Journal of Medical Sciences. PMID 31430035 DOI: 10.1002/kjm2.12114 |
0.342 |
|
| 2019 |
Hsu SJ, Chiu MC, Fang YJ, Yang TH, Yu JJ, Chen CC, Kuo CC, Lee JY, Chen CH, Chen DS, Kao JH. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. Journal of the Formosan Medical Association = Taiwan Yi Zhi. PMID 31279502 DOI: 10.1016/j.jfma.2019.06.014 |
0.3 |
|
| 2019 |
Chen CH, Chen CH, Lin CL, Lin CY, Hu TH, Tung SY, Hsieh SY, Lu SN, Chien RN, Hung CH, Sheen IS. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. Scientific Reports. 9: 7086. PMID 31068655 DOI: 10.1038/s41598-019-43554-3 |
0.314 |
|
| 2019 |
Chen CH. Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply. Alimentary Pharmacology & Therapeutics. 49: 1106-1107. PMID 30920034 DOI: 10.1111/apt.15183 |
0.302 |
|
| 2019 |
Chen CH, Hung CH, Wang JH, Lu SN, Lai HC, Hu TH, Lin CH, Peng CY. The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. The Journal of Infectious Diseases. PMID 30689910 DOI: 10.1093/infdis/jiy697 |
0.338 |
|
| 2018 |
Sou FM, Wu CK, Chang KC, Lu SN, Wang JH, Hung CH, Chen CH, Kee KM, Yen YH, Lin MT, Tsai MC, Hu TH. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. Journal of the Formosan Medical Association = Taiwan Yi Zhi. PMID 30527565 DOI: 10.1016/j.jfma.2018.10.017 |
0.355 |
|
| 2018 |
Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. Journal of the Formosan Medical Association = Taiwan Yi Zhi. PMID 30527436 DOI: 10.1016/j.jfma.2018.11.008 |
0.306 |
|
| 2018 |
Kuo MT, Hu TH, Hung CH, Wang JH, Lu SN, Tsai KL, Chen CH. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Alimentary Pharmacology & Therapeutics. PMID 30484881 DOI: 10.1111/apt.15053 |
0.309 |
|
| 2018 |
Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH, Peng CY. Modified FIB-4 index stratifies hepatocellular carcinoma risk in chronic hepatitis B patients on entecavir therapy. Journal of Gastroenterology and Hepatology. PMID 29968933 DOI: 10.1111/jgh.14372 |
0.365 |
|
| 2018 |
Kuo MT, Tseng PL, Chou YP, Chang KC, Tsai MC, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. The role of HBsAg in HBV relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. Journal of Gastroenterology and Hepatology. PMID 29514418 DOI: 10.1111/jgh.14142 |
0.303 |
|
| 2017 |
Chen CH, Hsu YC, Lu SN, Hung CH, Wang JH, Lee CM, Hu TH. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. Journal of Viral Hepatitis. PMID 29274189 DOI: 10.1111/jvh.12851 |
0.313 |
|
| 2017 |
Chen CH, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH, Peng CY. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget. 8: 92431-92441. PMID 29190928 DOI: 10.18632/oncotarget.21369 |
0.32 |
|
| 2017 |
Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, Wu CK, Lin JT, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 29164767 DOI: 10.1111/liv.13633 |
0.321 |
|
| 2017 |
Huang CM, Hu TH, Chang KC, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hung CH, Cho CL, Wu CK. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents. Medicine. 96: e8696. PMID 29145306 DOI: 10.1097/MD.0000000000008696 |
0.335 |
|
| 2017 |
Yen YH, Tsai MC, Wu CK, Chang KC, Hung CH, Chiu KW, Lu SN, Wang JH, Chen CH, Kee KM, Kuo YH, Tseng PL, Lin MT, Huang CM, Lin JT, et al. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study. Journal of the Formosan Medical Association = Taiwan Yi Zhi. PMID 29089161 DOI: 10.1016/j.jfma.2017.10.003 |
0.333 |
|
| 2017 |
Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN. The ALBI grade predicts the prognosis of patients with advanced hepatocellular carcinoma received sorafenib. Journal of Gastroenterology and Hepatology. PMID 28295594 DOI: 10.1111/jgh.13783 |
0.302 |
|
| 2017 |
Hung CH, Wang JH, Lu SN, Hu TH, Lee CM, Chen CH. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analog therapy. Journal of Viral Hepatitis. PMID 28130815 DOI: 10.1111/jvh.12683 |
0.316 |
|
| 2016 |
Chien TL, Wang JH, Kee KM, Chen CH, Hung CH, Lu SN. Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function. Plos One. 11: e0166543. PMID 27935953 DOI: 10.1371/journal.pone.0166543 |
0.311 |
|
| 2016 |
Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, Lu SN. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful anti-viral therapy. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 27254286 DOI: 10.1111/liv.13179 |
0.336 |
|
| 2016 |
Wu CK, Chang KC, Hung CH, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hu TH. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. The Journal of Antimicrobial Chemotherapy. PMID 27073265 DOI: 10.1093/jac/dkw097 |
0.355 |
|
| 2015 |
Chang KC, Tseng PL, Wu YY, Hung HC, Huang CM, Lu SN, Wang JH, Lee CM, Chen CH, Tsai MC, Yen YH, Lin MT, Wu CK, Huang CC, Chen HH, et al. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 13: 1017-24. PMID 25460552 DOI: 10.1016/j.cgh.2014.10.035 |
0.327 |
|
| 2015 |
Pei SN, Chen CH. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leukemia & Lymphoma. 56: 1611-8. PMID 25248874 DOI: 10.3109/10428194.2014.964699 |
0.321 |
|
| 2014 |
Chen CH, Lu SN, Lee CM, Hung CH, Wang JH, Hu TH. Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion. Hepatology International. 8: 365-74. PMID 26202639 DOI: 10.1007/s12072-014-9542-8 |
0.32 |
|
| 2014 |
Hung CH, Chiu YC, Hu TH, Chen CH, Lu SN, Huang CM, Wang JH, Lee CM. Significance of vitamin d receptor gene polymorphisms for risk of hepatocellular carcinoma in chronic hepatitis C. Translational Oncology. 7: 503-7. PMID 24894441 DOI: 10.1016/j.tranon.2014.05.001 |
0.309 |
|
| 2014 |
Tsai MC, Yu HC, Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH, Hu TH. Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. Journal of Gastroenterology and Hepatology. 29: 568-75. PMID 24716215 DOI: 10.1111/jgh.12436 |
0.306 |
|
| 2014 |
Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN, Lee CM. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. Journal of Hepatology. 60: 1127-34. PMID 24583247 DOI: 10.1016/j.jhep.2014.02.013 |
0.314 |
|
| 2014 |
Chen BB, Shih IL, Wu CH, Hsu C, Chen CH, Shih TT, Liu KL, Liang PC. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies. Journal of Vascular and Interventional Radiology : Jvir. 25: 371-8. PMID 24468045 DOI: 10.1016/j.jvir.2013.10.027 |
0.341 |
|
| 2013 |
Yang SC, Lu SN, Lee CM, Hu TH, Wang JH, Hung CH, Changchien CS, Chen CH. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion. Hepatology International. 7: 489-99. PMID 26201781 DOI: 10.1007/s12072-012-9382-3 |
0.304 |
|
| 2013 |
Wang HM, Hung CH, Lu SN, Chen CH, Lee CM, Hu TH, Wang JH. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. Liver International : Official Journal of the International Association For the Study of the Liver. 33: 756-61. PMID 23405889 DOI: 10.1111/liv.12118 |
0.333 |
|
| 2013 |
Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH, Tai WC, Tsai LS, Chen SC, Lin SC, Lu SN. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. The American Journal of Gastroenterology. 108: 416-24. PMID 23318478 DOI: 10.1038/ajg.2012.445 |
0.341 |
|
| 2012 |
Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, Yen MF, Lin SC, Yen YH, Tsai MC, Tseng PL, Hu TH. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. The Journal of Antimicrobial Chemotherapy. 67: 2766-72. PMID 22899800 DOI: 10.1093/jac/dks269 |
0.344 |
|
| 2012 |
Wang JH, Chuah SK, Lu SN, Hung CH, Chen CH, Kee KM, Chang KC, Tai WC, Hu TH. Transient elastography and simple blood markers in the diagnosis of esophageal varices for compensated patients with hepatitis B virus-related cirrhosis. Journal of Gastroenterology and Hepatology. 27: 1213-8. PMID 22432969 DOI: 10.1111/j.1440-1746.2012.07132.x |
0.323 |
|
| 2011 |
Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Antiviral Therapy. 16: 959-68. PMID 22024511 DOI: 10.3851/IMP1842 |
0.308 |
|
| 2011 |
Nien HC, Sheu JC, Kao JH, Chou HC, Su CW, Chen CH. Aboriginal Taiwanese hepatitis B carriers have more favorable viral factors than Han Chinese carriers. Journal of Medical Virology. 83: 1326-31. PMID 21678436 DOI: 10.1002/jmv.22135 |
0.334 |
|
| 2011 |
Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. International Journal of Cancer. 128: 2344-52. PMID 20669224 DOI: 10.1002/ijc.25585 |
0.375 |
|
| 2010 |
Kuo YH, Lu SN, Hung CH, Kee KM, Chen CH, Hu TH, Lee CM, Changchien CS, Wang JH. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. Hepatology International. 4: 700-6. PMID 21286340 DOI: 10.1007/s12072-010-9223-1 |
0.344 |
|
| 2010 |
Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, Lu SN. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. Journal of Gastroenterology and Hepatology. 25: 964-9. PMID 20546451 DOI: 10.1111/j.1440-1746.2009.06194.x |
0.316 |
|
| 2010 |
Yu ML, Lee CM, Chuang WL, Lu SN, Dai CY, Huang JF, Lin ZY, Hu TI, Chen CH, Hung C, Wang JH, Chen CL, Kao JH, Lai MY, Liu CH, et al. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses Journal of Infectious Diseases. 202: 86-92. PMID 20482252 DOI: 10.1086/653209 |
0.323 |
|
| 2010 |
Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH, Lee CM, Wang JH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. European Journal of Cancer (Oxford, England : 1990). 46: 744-51. PMID 20060710 DOI: 10.1016/j.ejca.2009.12.018 |
0.315 |
|
| 2010 |
Tung HD, Wang JH, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Lu SN. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. The American Journal of Gastroenterology. 105: 624-31. PMID 20051944 DOI: 10.1038/ajg.2009.711 |
0.332 |
|
| 2009 |
Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Annals of Hematology. 89: 255-62. PMID 19697028 DOI: 10.1007/s00277-009-0806-7 |
0.332 |
|
| 2009 |
Chen CH, Changchien CS, Lee CM, Tung WC, Hung CH, Hu TH, Wang JH, Wang JC, Lu SN. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. International Journal of Cancer. Journal International Du Cancer. 125: 621-9. PMID 19431214 DOI: 10.1002/ijc.24416 |
0.343 |
|
| 2008 |
Chen CH, Changchien CS, Lee CM, Hung CH, Hu TH, Wang JH, Wang JC, Lu SN. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. The Journal of Infectious Diseases. 198: 1634-42. PMID 18939932 DOI: 10.1086/592990 |
0.324 |
|
| 2008 |
Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY, Lu SN. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. Journal of Gastroenterology. 43: 159-70. PMID 18306990 DOI: 10.1007/s00535-007-2134-9 |
0.317 |
|
| 2007 |
Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology. 133: 1466-74. PMID 17915220 DOI: 10.1053/J.GASTRO.2007.09.002 |
0.304 |
|
| 2007 |
Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 106: 148-55. PMID 17339159 DOI: 10.1016/S0929-6646(09)60231-X |
0.302 |
|
| 2006 |
Chen CH, Huang GT, Yang PM, Chen PJ, Lai MY, Chen DS, Wang JD, Sheu JC. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. European Journal of Cancer (Oxford, England : 1990). 42: 2524-9. PMID 16920352 DOI: 10.1016/j.ejca.2006.06.007 |
0.352 |
|
| 2006 |
Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Chen CH. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. International Journal of Cancer. Journal International Du Cancer. 119: 1946-52. PMID 16708389 DOI: 10.1002/ijc.22045 |
0.351 |
|
| 2006 |
Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, Yu CY, Wen CL, Lu FJ, Chow LP. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics. 6: 2865-73. PMID 16586433 DOI: 10.1002/PMIC.200500488 |
0.33 |
|
| 2005 |
Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. Journal of Gastroenterology and Hepatology. 20: 1553-9. PMID 16174073 DOI: 10.1111/j.1440-1746.2005.03925.x |
0.356 |
|
| 2005 |
Lee CM, Hung CH, Lu SN, Wang JH, Tung HD, Huang WS, Chen CL, Chen WJ, Changchien CS. Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan. Intervirology. 49: 76-81. PMID 16166793 DOI: 10.1159/000087267 |
0.303 |
|
| 2005 |
Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, Changchien CS. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. Journal of Gastroenterology and Hepatology. 20: 727-32. PMID 15853986 DOI: 10.1111/J.1440-1746.2005.03791.X |
0.303 |
|
| 2005 |
Huang YH, Wu JC, Chen CH, Chang TT, Lee PC, Chau GY, Lui WY, Chang FY, Lee SD. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver International : Official Journal of the International Association For the Study of the Liver. 25: 236-41. PMID 15780044 DOI: 10.1111/j.1478-3231.2005.01081.x |
0.376 |
|
| 2004 |
Hung CH, Lee CM, Wang JH, Chen CH, Lu SN. Acute hepatitis B virus superinfection in a Taiwanese patient with chronic hepatitis C. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 103: 302-5. PMID 15175827 |
0.331 |
|
| 2004 |
Chen CH, Eng HL, Lee CM, Kuo FY, Lu SN, Huang CM, Tung HD, Chen CL, Changchien CS. Correlations between hepatitis B virus genotype and cirrhotic or non-cirrhotic hepatoma. Hepato-Gastroenterology. 51: 552-5. PMID 15086200 |
0.301 |
|
| 2004 |
Chen CH, Chen YY, Chen GH, Yang SS, Tang HS, Lin HH, Lin DY, Lo SK, Du JM, Chang TT, Chen SC, Liao LY, Kuo CH, Lin KC, Tai DI, et al. Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. Journal of Hepatology. 40: 653-9. PMID 15030982 DOI: 10.1016/J.Jhep.2003.12.002 |
0.328 |
|
| 2003 |
Hung CH, Lu SN, Wang JH, Lee CM, Chen TM, Tung HD, Chen CH, Huang WS, Changchien CS. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. Journal of Gastroenterology. 38: 153-7. PMID 12640529 DOI: 10.1007/s005350300025 |
0.314 |
|
| 2003 |
Lee C, Huang C, Lu S, Chen C, Chen L, Wang J, Tung H, Eng H, Changchien C. Ultrasonography and clinical features of hepatitis B virus-related hepatocellular carcinoma in noncirrhotic and cirrhotic liver Ultrasound in Medicine & Biology. 29: S199. DOI: 10.1016/S0301-5629(03)00781-6 |
0.327 |
|
| 2002 |
Liang RJ, Chen CH, Chang YC, Hu RH, Sheu JC. Pedunculated hepatic hemangioma: report of two cases. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 101: 437-41. PMID 12189652 |
0.356 |
|
| 2000 |
Lu SN, Lee CM, Changchien CS, Chen CJ. Excess mortality from hepatocellular carcinoma in an HCV-endemic township of an HBV-endemic country (Taiwan). Transactions of the Royal Society of Tropical Medicine and Hygiene. 93: 600-2. PMID 10717743 DOI: 10.1016/S0035-9203(99)90063-9 |
0.338 |
|
| 1999 |
Tai DI, Changchien CS, Hung CS, Chen CJ. Replication of hepatitis B virus in first-degree relatives of patients with hepatocellular carcinoma. The American Journal of Tropical Medicine and Hygiene. 61: 716-9. PMID 10586900 DOI: 10.4269/AJTMH.1999.61.716 |
0.344 |
|
| 1999 |
Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, Wang JH, Lin DY, Chen CL, Chen WJ. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 86: 1143-50. PMID 10506697 DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1143::AID-CNCR7>3.0.CO;2-Z |
0.334 |
|
| Show low-probability matches. |